After primary treatment of localised prostate cancer (PCa), 30-50% of patients develop a biochemical recurrence. For patients with biochemical (and local) recurrent PCa after prostatectomy, salvage external beam radiotherapy (sEBRT) is an established curative treatment option. Detection of metastatic disease outside the prostate bed helps identifying a substantial number of patients with oligometastasis, for which local sEBRT is not indicated.
PSMA PET/CT scan has shown an excellent detection rate in recurrent PSA and therefore offers an excellent diagnostic tool for optimal patient selection for local sEBRT and/or a more personal approach if oligometastatic disease is identified. This early detection using the PSMA PET scan has led to a remarkable increase in the number of diagnosed patients with oligometastatic Pca where the metastasis directed radiotherapy (MDRT) to all visible disease mostly the treatment of choice. However, current knowledge on the timing of PSMA PET/CT in recurrence and the interpretation of images is still primitive.
The aim of this Research Topic is to generate a discussion in recent developments in treatment of recurrent prostate cancer using the new generation imaging modalities and to give an overview of on-going research in recurrent PCa. We welcome Original Research Articles, Review and Systematic Reviews.
Topics of interest include:
-Role and studies involving PSMA PET/MRI in prostate cancer
-MR Imaging to PSMA PET/CT in PCa recurrence
-Radiotherapies in local recurrence and/or oligorecurrent prostate cancer
-Patterns and treatment of local recurrence after RARP based on PSMA scan
-Local treatment protocols in metastasis directed radiotherapy (MDRT)
-Patterns of recurrence after MDRT for oligometastatic prostate cancer
- (new generation) Androgen deprivation therapy in combination with sEBRT/MDRT.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
After primary treatment of localised prostate cancer (PCa), 30-50% of patients develop a biochemical recurrence. For patients with biochemical (and local) recurrent PCa after prostatectomy, salvage external beam radiotherapy (sEBRT) is an established curative treatment option. Detection of metastatic disease outside the prostate bed helps identifying a substantial number of patients with oligometastasis, for which local sEBRT is not indicated.
PSMA PET/CT scan has shown an excellent detection rate in recurrent PSA and therefore offers an excellent diagnostic tool for optimal patient selection for local sEBRT and/or a more personal approach if oligometastatic disease is identified. This early detection using the PSMA PET scan has led to a remarkable increase in the number of diagnosed patients with oligometastatic Pca where the metastasis directed radiotherapy (MDRT) to all visible disease mostly the treatment of choice. However, current knowledge on the timing of PSMA PET/CT in recurrence and the interpretation of images is still primitive.
The aim of this Research Topic is to generate a discussion in recent developments in treatment of recurrent prostate cancer using the new generation imaging modalities and to give an overview of on-going research in recurrent PCa. We welcome Original Research Articles, Review and Systematic Reviews.
Topics of interest include:
-Role and studies involving PSMA PET/MRI in prostate cancer
-MR Imaging to PSMA PET/CT in PCa recurrence
-Radiotherapies in local recurrence and/or oligorecurrent prostate cancer
-Patterns and treatment of local recurrence after RARP based on PSMA scan
-Local treatment protocols in metastasis directed radiotherapy (MDRT)
-Patterns of recurrence after MDRT for oligometastatic prostate cancer
- (new generation) Androgen deprivation therapy in combination with sEBRT/MDRT.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
